Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Affymetrix Completes Acquisition of eBioscience Holding Company, Inc.

Published: Thursday, June 28, 2012
Last Updated: Thursday, June 28, 2012
Bookmark and Share
Acquisition expands Affymetrix’s addressable markets by more than $2.5 billion per year.

Affymetrix Inc. has announced that the Company has completed its acquisition of eBioscience Holding Company, Inc., a privately-held company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics.

The acquisition enhances Affymetrix’s product portfolio and expands its addressable markets by more than $2.5 billion per year.

“This transaction is an important strategic step for Affymetrix. Through the acquisition of eBio we now have a blue-chip portfolio of cell-based assays that diversify our business and open up important new avenues for growth,” said Dr. Frank Witney, president and chief executive officer of Affymetrix.

Dr. Witney continued, “With eBio’s portfolio of profitable and growing flow cytometry and immunoassay reagents, the combined Company intends to provide novel molecular solutions that will allow us to penetrate sizable new markets.”

“Together we expect to generate enhanced operating leverage and profitability,” stated Tim Barabe, executive vice president and chief financial officer. “The combination is expected to be accretive to gross margins and operating income in fiscal 2012.”

eBioscience will operate as a separate business unit within Affymetrix under its existing leadership team.

“The combination of these two industry-leaders will extend our global commercial reach and create important cross-selling opportunities, as well as the opportunity to combine technologies to create important new products,” said Don Tartre, general manager of eBio. “Together we can enhance our value to customers while accelerating important scientific discoveries.”

Under the terms of the agreement, Affymetrix paid approximately $315 million in cash to acquire eBioscience, funded through a new senior secured credit facility, an offering of convertible notes and other available cash resources.

As a result of the merger, eBioscience has become a wholly-owned subsidiary of Affymetrix.

In connection with the acquisition of eBioscience, Affymetrix’s Compensation Committee approved equity incentive awards to 278 eBioscience employees as inducement to join Affymetrix.

An aggregate 1.32 million shares of Affymetrix common stock may be issued to these new non-executive employees under the awards, which include an aggregate 942,000 restricted stock units that vest in equal installments over two years, subject to performance based criteria, 296,650 restricted stock units that vest in equal installments over four years and options to purchase up to 80,000 shares of common stock that vest in equal installments over four years. The stock options have a maximum term of 7 years.

The equity incentive awards were granted as inducements material to the new employees entering into employment with Affymetrix in accordance with NASDAQ Listing Rule 5635(c)(4).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Acquires Affymetrix
Thermo Fisher Scientific and Affymetrix, has announced that Thermo Fisher has completed its previously announced acquisition of Affymetrix for $14.00 per share in cash, for a total purchase price of approximately $1.3 billion.
Friday, April 01, 2016
Groupe Grimaud Chooses Affymetrix Genotyping Arrays
Affymetrix, Inc. has announced that one of the world’s largest producers of breeding chickens – Roussay, France-based Groupe Grimaud – will use the Axiom® genotyping platform from Affymetrix in its genomic selection and poultry breeding program.
Thursday, February 25, 2016
Bio-Genesys, Affymetrix Partner
Partnership to offer animal genomic testing services to professional farming operations.
Wednesday, January 13, 2016
Thermo Fisher Scientific to Acquire Affymetrix
Strengthens leadership in biosciences and genetic analysis.
Monday, January 11, 2016
Affymetrix, Reveal Biosciences Partner
Partnership agreement to offer RNA ISH tissue staining, imaging, and image analysis services.
Thursday, December 03, 2015
Affymetrix and Athletigen Partner
Partnership agreement to advance genetics in human athletic performance.
Thursday, October 29, 2015
Affymetrix and Luminex Announce Distribution Agreement
Agreement for multiplexed assay instrument platform.
Friday, October 16, 2015
Green Super Rice Project Selects Affymetrix Genotyping Platform for Developing New Rice Varieties
The Green Super Rice (GSR) project includes building a highly efficient genotyping platform for the large-scale molecular breeding activities within the international rice research community.
Tuesday, September 22, 2015
Affymetrix, BioRealm, RUCDR Ally
Affymetrix, BioRealm, and RUCDR Infinite Biologics today announced a strategic alliance to genotype the National Institute of Drug Abuse biorepository.
Wednesday, July 08, 2015
Affymetrix Acquires Assets of Eureka Genomics
Aquisition will enable provision of high throughput and economical crop and animal genotyping.
Thursday, May 14, 2015
CollabRx, Affymetrix To Develop Analytical Tools For Integrated Clinical Cancer Panels
The overall objective of the partnership is to provide scientific knowledge for biomarker CNV profiles in cancer.
Wednesday, April 16, 2014
University of Bristol Collaborates with Affymetrix on Genotyping Arrays
Results from the array presented at the 2014 Plant and Animal Genome conference.
Wednesday, January 15, 2014
Affymetrix Reports 2013 First Quarter Results
Affymetrix, Inc. reported its operating results for the three months ended March 31, 2013.
Wednesday, May 01, 2013
Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data
Generated from FFPE solid tumor samples for accelerating cancer translational research.
Thursday, April 11, 2013
Ingenuity Systems and Affymetrix Partner
Companies collaborate to eliminate microarray expression analysis bottleneck.
Monday, April 08, 2013
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
Plant Analysis – Identifying Metabolites
New plant analysis method shows biologically active plant substances are far more common than previously thought.
New Mechanism to Control Human Viral Infections Discovered
Researchers discover long sought after mechanism in human cells that could help treat diseases caused by viruses.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
Immune-Cell Traps May Aid Cancer Metastasis
Study suggests cancer cells can induce neutrophils to release traps which the cells use to capture pathogens.
Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!